602964 Disclosed is the use of a monoclonal antibody or an antigen-binding fragment thereof specific for human Fas ligand protein (FasL), wherein said monoclonal antibody comprises at least one heavy chain variable region and at least one light chain variable region, wherein the amino acid sequences of the complementary determining region (CDRs) of the heavy chain are: (a1) CDR H1: Asn Tyr Trp Ile Gly (SEQ ID NO:1) or a sequence that has at least 70% sequence identity to SEQ ID NO:1, (b1) CDR H2:Tyr Leu Tyr Pro Gly Gly Leu Tyr Thr Asn Tyr Asn Glu Lys Phe Lys Gly (SEQ ID NO:2) or a sequence that has at least 70% sequence identity to SEQ ID NO:2, (c1) CDR H3:Tyr Arg Asp Tyr Asp Tyr Ala Met Asp Tyr (SEQ ID NO:3) or a sequence that has at least 70% sequence identity to SEQ ID NO:3 and the amino acid sequences of the complementary determining regions (CDRs) of the light chain are (a2) CDR L1:Lys Ser Thr Lys Ser Leu Leu Asn Ser Asp Gly Phe Thr Tyr Leu Gly (SEQ ID NO:4) or a sequence that has at least 70% sequence identity to SEQ ID NO:4, (b2) CDR L2:Leu Val Ser Asn Arg Phe Ser (SEQ ID NO:5) or a sequence that has at least 70% sequence identity to SEQ ID NO:5, (c2) CDR L3:Phe Gln Ser Asn Tyr Leu Pro Leu Thr (SEQ ID NO:6) or a sequence that has at least 70% sequence identity to SEQ ID NO:6 for the manufacture of a medicament for the prevention and/or treatment of a skin disease associated with keratinocyte acantholysis.
